Aileron Therapeutics is a clinical stage chemoprotection oncology company. Co.'s product candidate, ALRN-6924, is a MDM2/MDMX dual inhibitor that utilizes its proprietary peptide drug technology. When used as a chemoprotective agent, ALRN-6924 is designed to activate p53, which in turn upregulates p21, an inhibitor of the cell replication cycle. ALRN-6924 is a chemoprotective agent in clinical development to employ a biomarker strategy, in which Co. focuses on treating patients with p53-mutated cancers. The ALRN average annual return since 2017 is shown above.
The Average Annual Return on the ALRN average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ALRN average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ALRN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free ALRN Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
